ACADIA Pharmaceuticals' ENHANCE-1 Phase III trial involving pimavanserin has been initiated to assess the ability of pimavanserin to treat schizophrenia in patients who have had a negative response to the antipsychotic therapies currently in use. Read More »

Anthera Pharmaceuticals' Phase 2 BRIGHT-SC trial data has been selected as a poster presentation at the 2016 American Society of Nephrology’s Kidney Week Annual Meeting. Read More »

Momenta Pharmaceuticals and Mylan N.V.'s first patient in its Phase 1 study of M834 has been dosed. The trial will evaluate M834's pharmacokinetics, safety and immunogenicity. Read More »

Ajanta Pharma USA, subsidiary of Ajana Pharma Ltd., India, has released Amlodipine + Olmesartan Medoxomil Tablets in the United States. Read More »

Aralez Pharmaceuticals Trading DAC has finalized the purchase of the rights to Toprol-XL in the U.S. and Authorized Generic from AstraZeneca. Read More »

ACADIA Pharmaceuticals' Phase II SERENE trial involving pimavanserin has begun. Read More »

The Female Health Co.'s transformational merger with Aspen Park Pharmaceuticals has been finalized with both sides agreeing to modified terms. Read More »

A licensing agreement with Norgine B.V. will give Valeant Pharmaceuticals the rights to the development and commercialization of NER1006 Powder for Oral Solution in the United States and Canada. Read More »

Valeant Pharmaceuticals and Progenics Pharmaceuticals have commercially released RELISTOR Tablets in the United States and it is now available for prescription. Read More »

ACADIA Pharmaceuticals has started its Phase II clinical trial of pimavanserin called SERENE to assess the medication’s ability to treat patients who have Alzheimer’s disease and are experiencing agitation. Read More »

Braeburn Pharmaceuticals and Camurus have extended their partnership and license agreement to include buprenorphine combination products. Read More »

Eiger BioPharmaceuticals' hepatitis delta campaign has been launched across the country. Read More »

Sunovion Pharmaceuticals' acquisition of Cynapsus Therapeutics has been finalized through Sunovion's subsidiary Sunovion CNS Development Canada. Read More »

CymaBay Therapeutics will present results of its Phase 2 proof-of-concept MBX-8025 clinical trial at the Annual Meeting of the American Association for the Study of Liver Diseases Nov. 11-15 in Boston. Read More »

Arrow Pharmaceuticals intends to give two presentations at The Liver Meeting 2016 on its investigational medicine designed to treat liver disease linked to alpha-1 antitrypsin deficiency, ARC-AAT. Read More »

CVS Health has launched CVS Pay across the country. Read More »